• ქართული
  • English
  • Bristol-Myers to buy Celgene for $74 billion

    Cancer drugmaker Bristol-Myers Squibb Co said on Thursday it would buy Celgene Corp for about $74 billion in a cash-and-stock deal.

    Market Quotes by TradingView